Clinical Research Directory
Browse clinical research sites, groups, and studies.
An Open Label Extension Safety Study to Evaluate SD-101 in Epidermolysis Bullosa
Sponsor: Paradigm Therapeutics
Summary
The objective is to characterize the continued safety of SD-101 cream containing 6% allantoin in the treatment of the skin in patients with Simplex, Recessive Dystrophic, or JEB-nH EB.
Official title: An Open Label Extension, Multi-Center Study to Evaluate the Safety of SD 101 Cream in Subjects With Epidermolysis Bullosa
Key Details
Gender
All
Age Range
28 Days - 12 Years
Study Type
INTERVENTIONAL
Enrollment
80
Start Date
2026-07-15
Completion Date
2027-08-19
Last Updated
2026-03-19
Healthy Volunteers
No
Conditions
Interventions
SD-101 Dermal Cream (6%)
SD-101 is a white, crystalline powder that is formulated within an odorless, soft, white cream base. SD-101-6.0 cream contains allantoin, a diureide glyoxylic acid, at a concentration of 6% and other excipients.